Neogenomics Sustainability Profile
NeoGenomics Laboratories, a leading provider of cancer-focused genetic testing services, is headquartered in the United States. Founded in 2001, the company has established itself as a key player in the oncology diagnostics industry, with major operational regions across North America and Europe. NeoGenomics offers a comprehensive range of services, including molecular testing, pathology, and clinical trial support, distinguished by their commitment to innovation and accuracy. Their advanced testing capabilities, such as next-generation sequencing and liquid biopsy, set them apart in a competitive market. With a strong market position, NeoGenomics has achieved notable milestones, including partnerships with prominent healthcare institutions and a growing portfolio of proprietary tests. Their dedication to improving patient outcomes through precision medicine continues to drive their success in the evolving landscape of cancer diagnostics.
DitchCarbon Score
How does Neogenomics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neogenomics's score of 23 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neogenomics's reported carbon emissions
In 2023, NeoGenomics, headquartered in the US, reported total carbon emissions of approximately 4,717,000 kg CO2e, which includes 536,000 kg CO2e from Scope 1 emissions and 4,181,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Despite the significant emissions figures, NeoGenomics has not set specific reduction targets or initiatives as part of their climate commitments. There are no reported climate pledges or SBTi (Science Based Targets initiative) targets, indicating a potential area for future development in their sustainability strategy. As the company continues to operate within the healthcare sector, addressing carbon emissions and establishing clear reduction goals will be crucial for aligning with industry standards and responding to increasing environmental expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 536,000 |
| Scope 2 | 4,181,000 |
| Scope 3 | - |
How Carbon Intensive is Neogenomics's Industry?
How Carbon Intensive is Neogenomics's Location?
Neogenomics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Neogenomics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
